- Investing Ideas
- /
- U.S. Pharmaceuticals & Biotech The Future Is Online
U.S. Pharmaceuticals & Biotech The Future Is Online
UPDATED Dec 03, 2023
A list of some of the world's largest online retailers.
315 companies
| Company | Last Price | 7D Return | 1Y Return | Market Cap | Analysts Target | Valuation | Growth | Div Yield | ||
|---|---|---|---|---|---|---|---|---|---|---|
| BGNEBeiGene | US$187.49 | 2.5% | -0.6% | US$19.5b | US$285.19 | PS8.9x | E56.5% | n/a | ||
| ILMNIllumina | US$109.79 | 16.0% | -48.7% | US$17.4b | US$153.35 | PS3.9x | E80.3% | n/a | ||
| BMRNBioMarin Pharmaceutical | US$92.42 | 4.3% | -10.7% | US$17.4b | US$110.59 | PE118.4x | E40.6% | n/a | ||
| WATWaters | US$288.85 | 4.3% | -15.1% | US$17.1b | US$272.06 | PE26.2x | E5.9% | n/a | ||
| RPRXRoyalty Pharma | US$27.35 | 0.8% | -36.4% | US$16.3b | US$47.88 | PE66x | E88.1% | 2.9% | ||
| AVTRAvantor | US$21.38 | 6.6% | -4.3% | US$14.5b | US$23.25 | PE39.7x | E29.9% | n/a | ||
| EXASExact Sciences | US$67.03 | 1.8% | 47.2% | US$12.1b | US$90.02 | PS5x | E65.4% | n/a | ||
| INCYIncyte | US$54.02 | 2.2% | -35.8% | US$12.1b | US$76.16 | PE28.5x | E29.1% | n/a | ||
| NBIXNeurocrine Biosciences | US$117.12 | 3.6% | -5.5% | US$11.5b | US$135.27 | PE60.2x | E36.1% | n/a | ||
| UTHRUnited Therapeutics | US$240.73 | 4.2% | -12.1% | US$11.3b | US$281.88 | PE12.6x | E11.2% | n/a | ||
| RVTYRevvity | US$91.28 | 3.4% | -33.3% | US$11.3b | US$106.71 | PE52.8x | E-8.8% | 0.3% | ||
| VTRSViatris | US$9.37 | 0.3% | -14.2% | US$11.2b | US$11.61 | PE6.1x | E-11.0% | 5.1% | ||
| LEGNLegend Biotech | US$59.99 | -2.6% | 17.7% | US$10.9b | US$87.69 | PS46.7x | E64.4% | n/a | ||
| TEVATeva Pharmaceutical Industries | US$9.71 | -1.7% | 12.6% | US$10.9b | US$11.05 | PB1.6x | E64.8% | 0% | ||
| CRLCharles River Laboratories International | US$201.68 | 3.6% | -6.2% | US$10.3b | US$213.47 | PE21.8x | E11.2% | n/a | ||
| TECHBio-Techne | US$64.57 | 3.7% | -21.8% | US$10.2b | US$77.69 | PE41.4x | E9.6% | 0.5% | ||
| QGENQiagen | US$41.45 | 2.1% | -15.7% | US$9.5b | US$48.47 | PE19.5x | E7.5% | n/a | ||
| RGENRepligen | US$164.94 | 3.4% | -7.7% | US$9.2b | US$171.38 | PE79.5x | E10.0% | n/a | ||
| BRKRBruker | US$66.06 | 2.3% | -1.5% | US$9.1b | US$70.56 | PE28.7x | E12.0% | 0.3% | ||
| BIOBio-Rad Laboratories | US$307.00 | -0.05% | -24.3% | US$8.9b | US$444.60 | PS3.3x | E57.6% | n/a | ||
| MEDPMedpace Holdings | US$275.41 | -0.2% | 34.0% | US$8.5b | US$278.60 | PE31x | E14.6% | n/a | ||
| ROIVRoivant Sciences | US$9.85 | 8.2% | 59.4% | US$7.9b | US$15.75 | PS76.8x | E35.9% | n/a | ||
| SRPTSarepta Therapeutics | US$84.44 | 2.3% | -31.3% | US$7.9b | US$139.22 | PS7.1x | E66.7% | n/a | ||
| IMGNImmunoGen | US$29.32 | 81.4% | 440.0% | US$7.8b | US$29.48 | PS27.3x | E59.4% | n/a |